<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531011</url>
  </required_header>
  <id_info>
    <org_study_id>07-380 RCT</org_study_id>
    <nct_id>NCT00531011</nct_id>
  </id_info>
  <brief_title>EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease</brief_title>
  <acronym>EXecutive</acronym>
  <official_title>EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this two part study is the assessment of the performance of the XIENCE V®
      Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific
      setting of patients with Multi-Vessel Coronary Artery Disease (MVD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical evaluation of the XIENCE V® everolimus eluting coronary stent system as a
      revascularization treatment of patients with multi-vessel coronary artery disease (MVD-CAD).

      The long term safety and efficacy of the XIENCE V EECSS have been demonstrated in the SPIRIT
      FIRST trial up to 5 years, the SPIRIT II trial up to 4 years, and in the SPIRIT III
      Randomized Control Trial (RCT) up to 3 years. In addition, these pre-approval studies have
      shown low rates of Target Vessel Failure and Major Adverse Cardiac Events (MACE) that were
      consistently lower than the comparator arm of each study.

      The post approval EXECUTIVE study demonstrated that the use of the XIENCE EECSS in complex
      lesions in a real-world population resulted in 1 year MACE, Stent Thrombosis and Target
      Lesion Revascularization rates that are comparable to those of the previously mentioned
      pre-approval studies which included patients with more restricted inclusion / exclusion
      criteria.

      Therefore, based on existing data from these trials, Abbott Vascular has decided to
      discontinue further follow up in the EXECUTIVE trial.

      The study is composed of two parts:

      A Registry, outlined in a separate posting and the Randomized Control Trial (RCT) portion of
      this study, which is as follows:

      -A randomized group of patients aimed at assessing the angiographic efficacy of the XIENCE V®
      Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) compared to the TAXUS® Liberté™
      Paclitaxel Eluting Coronary Stent System.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent Late Loss (LL)</measure>
    <time_frame>at 270 days</time_frame>
    <description>Full Analysis Set (FAS). LL is defined as the difference between the post-procedure (immediately post placement of the stent) minimal lumen diameter (MLD) and the follow-up MLD (at 270 days). In stent is measured within the confines of the stent edges.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent Binary Restenosis Rate</measure>
    <time_frame>at 9 months</time_frame>
    <description>This measures the percentage of patients who have &gt; 50% diameter stenosis of the assessed vessel, within the stent edges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Binary Restenosis Rate</measure>
    <time_frame>at 9 months</time_frame>
    <description>This measures the percentage of patients who have &gt; 50% diameter stenosis of the assessed vessel, within the stent edges
In-segment is measured within the confines of the stent edges plus within 5 mm on either side of the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Late Loss (LL)</measure>
    <time_frame>at 9 months</time_frame>
    <description>LL is defined as the difference between the post-procedure (immediately post placement of the stent) minimal lumen diameter (MLD) and the follow-up MLD (at 270 days). In segment LL is measured within the confines of the stent edges and within 5 mm of those edges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Rate of Cardiac Death, Myocardial Infarction (MI, Both Q-wave and Non Q-wave), and Ischemia-driven Target Lesion Revascularization (TLR) .</measure>
    <time_frame>at 30 days</time_frame>
    <description>This measure is a calculation of the percentage of participants who experience any of the components of this composite measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Rate of All Death, MI (Q-wave and Non Q-wave), and Target Vessel Revascularization (TVR).</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Success</measure>
    <time_frame>at the time of PCI</time_frame>
    <description>defined as attainment of &lt; 30% residual in-stent stenosis (by visual assessment) using any percutaneous method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>at the time of PCI</time_frame>
    <description>defined as: residual in-stent %DS of &lt; 30% using a percutaneous method, without cardiac death, Q-wave MI, non Q-wave MI, or repeat revasc of the target during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>at the time of PCI</time_frame>
    <description>defined as achievement of a final residual in-stent diameter stenosis of &lt; 30% (visual assessment) using the assigned device only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Stent Thrombosis.</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Stent Thrombosis.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularizations</measure>
    <time_frame>at 30 days</time_frame>
    <description>(TLR/TVR/any revascularization)both ischemia-driven and not ischemia-driven.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularizations</measure>
    <time_frame>9 months</time_frame>
    <description>(TLR/TVR/any revascularization)both ischemia-driven and not ischemia-driven.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death, MI (Q-wave and Non Q-wave), and Ischemia-driven TLR .</measure>
    <time_frame>9 months</time_frame>
    <description>ITT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Death, MI (Q-wave and Non Q-wave), and TVR.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent Minimum Lumen Diameter (MLD).</measure>
    <time_frame>at 9 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Minimum Lumen Diameter (MLD).</measure>
    <time_frame>at 9 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Minimum Lumen Diameter (MLD).</measure>
    <time_frame>at 9 months.</time_frame>
    <description>Proximal refers to the immediate 5 mm outside of the proximal end of the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Minimum Lumen Diameter (MLD).</measure>
    <time_frame>at 9 months.</time_frame>
    <description>Distal refers to the immediate 5 mm outside of the distal end of the stent.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Artery Restenosis</condition>
  <arm_group>
    <arm_group_label>XIENCE V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAXUS® Liberté™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE V® Everolimus Eluting Coronary Stent System</intervention_name>
    <description>Coronary artery placement of a drug-eluting stent</description>
    <arm_group_label>XIENCE V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</intervention_name>
    <description>Coronary artery placement of a drug-eluting stent</description>
    <arm_group_label>TAXUS® Liberté™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must be at least 18 years of age

          2. Patient is able to verbally confirm understanding of risks, benefits and treatment
             alternatives of receiving the XIENCE V® EECSS and he/she or his/her legally authorized
             representative provides written informed consent prior to any study related procedure,
             as approved by the appropriate Medical Ethics Committee of the respective clinical
             site

          3. Patient has been diagnosed a MVD, as documented by coronary angiography, i.e.
             presenting a severe stenosis (&gt;50%) amenable to PCI in at least 2 major epicardial
             vessels or their principal bifurcation branches (diagonal or obtuse marginal)

          4. Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,
             silent ischemia, positive functional study or a reversible change in the
             electrocardiogram -ECG- consistent with ischemia)

          5. Patient must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery

          6. Patient must agree to undergo all protocol-required follow-up examinations.

        Angiographic Inclusion Criteria

          1. Patients may receive up to 4 planned XIENCE V® EECSS stents, depending on the number
             of vessels treated and their respective lesion length. When multiple lesions are
             present in one or more main coronary branches, complete revascularization should be
             attempted with the implantation of a maximum of 4 planned stents

          2. Target lesions must be de novo lesions (no prior stent implant, no prior
             brachytherapy)

          3. Target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate

          4. Target lesion &lt; or = 28 mm in length by visual estimation

          5. Target lesions must be in a major artery or its principal branches (diagonal or obtuse
             marginal) with a visually estimated stenosis of &gt; or = 50%

          6. Two lesions in a single main coronary artery or its branches do not constitute a MVD
             situation, therefore this type of patient must not be enrolled

        Exclusion Criteria:

          1. Patient has had a known diagnosis of acute myocardial infarction (AMI) within 72 hours
             preceding the index procedure (non-procedural/spontaneous MI, CK-MB &gt; or = to 2 times
             upper limit of normal) and CK and CK-MB have not returned within normal limits at the
             time of procedure

          2. Patient has current unstable arrhythmias

          3. Patient has a known left ventricular ejection fraction (LVEF) &lt;30%

          4. Patient has received a heart transplant or any other organ transplant or is on a
             waiting list for any organ transplant

          5. Patient is receiving or scheduled to receive chemotherapy or radiation therapy within
             30 days prior to or after the procedure.

          6. Patient is receiving immunosuppression therapy or has known immunosuppressive or
             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus
             etc.)

          7. Patient is receiving chronic anticoagulation therapy (e.g. coumadin)

          8. Patient has a known hypersensitivity or contraindication to aspirin, paclitaxel,
             either heparin or bivalirudin, clopidogrel or ticlopidine, everolimus, cobalt,
             chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that
             cannot be adequately pre-medicated

          9. Elective surgery is planned within the first 9 months (+/- 14 days) after the
             procedure that will require discontinuing either aspirin or clopidogrel

         10. Patient has a platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3, a WBC of &lt;3,000
             cells/mm3, or documented or suspected liver disease (including laboratory evidence of
             hepatitis)

         11. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5
             mg/dl, patient on dialysis)

         12. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

         13. Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological
             attack (TIA) within the past six months

         14. Patient has had a significant GI or urinary bleed within the past six months

         15. Patient has other medical illness (e.g., cancer or congestive heart failure) or known
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause
             non-compliance with the protocol, confound the data interpretation or is associated
             with a limited life expectancy (i.e. less than one year)

         16. Patient is already participating in another investigational use device or drug study
             or has completed the follow-up phase of another study within the last 30 days.

        Angiographic Exclusion Criteria

          1. Target lesion meets any of the following criteria:

               -  Left main location

               -  Located within an arterial or saphenous vein graft or distal to a diseased
                  arterial or saphenous vein graft (defined as vessel irregularity per angiogram
                  and &gt;20% stenosed lesion by visual estimation)

               -  Heavy calcification

          2. The patient may need more than 4 planned stents. Bailout stents are allowed but must
             be of the same type as randomization stent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrado Vassanelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Civile Maggiore - Università di Verona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flavio Ribichini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Civile Maggiore - Università di Verona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. San Giovanni di Dio</name>
      <address>
        <city>Agrigento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Cannizzaro</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Vittorio Emanuele - Ferrarotto - S. Bambino</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Università Mater Domini c/o Campus Università Magna Grecia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria OO.RR Foggia</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.O. Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Loreto Mare</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. O. Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Madre Vannini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sandro Pertini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.S.O. Molinette San Giovanni Battista di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maria Vittoria</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. San Giovanni Bosco</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Giovanni Battista - Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria - Ospedale Riuniti Umberto I - G.M. Lancisi - G. Salesi</name>
      <address>
        <city>Torrette Di Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Maggiore - Università di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Vigevano</name>
      <address>
        <city>Vigevano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Della Provincia di Pavia</name>
      <address>
        <city>Voghera</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Marco</name>
      <address>
        <city>Zingonia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2007</study_first_submitted>
  <study_first_submitted_qc>September 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <results_first_submitted>May 16, 2011</results_first_submitted>
  <results_first_submitted_qc>July 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2011</results_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stents</keyword>
  <keyword>Drug-eluting Stent</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Coronary Artery stenosis</keyword>
  <keyword>Coronary Artery Stent Restenosis</keyword>
  <keyword>Stent Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The patient population was comprised of male and female patients derived from the general interventional cardiology population from 9 centers in Italy.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>XIENCE V</title>
          <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
        </group>
        <group group_id="P2">
          <title>TAXUS® Liberté™</title>
          <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>XIENCE V</title>
          <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
        </group>
        <group group_id="B2">
          <title>TAXUS® Liberté™</title>
          <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="10.1"/>
                    <measurement group_id="B2" value="63.8" spread="10.2"/>
                    <measurement group_id="B3" value="64.2" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>In-stent Binary Restenosis Rate</title>
        <description>This measures the percentage of patients who have &gt; 50% diameter stenosis of the assessed vessel, within the stent edges.</description>
        <time_frame>at 9 months</time_frame>
        <population>ITT, 167 patients performed angiographic follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent Binary Restenosis Rate</title>
          <description>This measures the percentage of patients who have &gt; 50% diameter stenosis of the assessed vessel, within the stent edges.</description>
          <population>ITT, 167 patients performed angiographic follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment Binary Restenosis Rate</title>
        <description>This measures the percentage of patients who have &gt; 50% diameter stenosis of the assessed vessel, within the stent edges
In-segment is measured within the confines of the stent edges plus within 5 mm on either side of the stent.</description>
        <time_frame>at 9 months</time_frame>
        <population>167 patients performed angiographic follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment Binary Restenosis Rate</title>
          <description>This measures the percentage of patients who have &gt; 50% diameter stenosis of the assessed vessel, within the stent edges
In-segment is measured within the confines of the stent edges plus within 5 mm on either side of the stent.</description>
          <population>167 patients performed angiographic follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment Late Loss (LL)</title>
        <description>LL is defined as the difference between the post-procedure (immediately post placement of the stent) minimal lumen diameter (MLD) and the follow-up MLD (at 270 days). In segment LL is measured within the confines of the stent edges and within 5 mm of those edges.</description>
        <time_frame>at 9 months</time_frame>
        <population>167 patients performed angiographic follow-up. Descriptive statistics for this measure are based on one random lesion per patient.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment Late Loss (LL)</title>
          <description>LL is defined as the difference between the post-procedure (immediately post placement of the stent) minimal lumen diameter (MLD) and the follow-up MLD (at 270 days). In segment LL is measured within the confines of the stent edges and within 5 mm of those edges.</description>
          <population>167 patients performed angiographic follow-up. Descriptive statistics for this measure are based on one random lesion per patient.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.100" spread="0.484"/>
                    <measurement group_id="O2" value="0.037" spread="0.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Rate of Cardiac Death, Myocardial Infarction (MI, Both Q-wave and Non Q-wave), and Ischemia-driven Target Lesion Revascularization (TLR) .</title>
        <description>This measure is a calculation of the percentage of participants who experience any of the components of this composite measure.</description>
        <time_frame>at 30 days</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Rate of Cardiac Death, Myocardial Infarction (MI, Both Q-wave and Non Q-wave), and Ischemia-driven Target Lesion Revascularization (TLR) .</title>
          <description>This measure is a calculation of the percentage of participants who experience any of the components of this composite measure.</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Rate of All Death, MI (Q-wave and Non Q-wave), and Target Vessel Revascularization (TVR).</title>
        <time_frame>at 30 days</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Rate of All Death, MI (Q-wave and Non Q-wave), and Target Vessel Revascularization (TVR).</title>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Success</title>
        <description>defined as attainment of &lt; 30% residual in-stent stenosis (by visual assessment) using any percutaneous method.</description>
        <time_frame>at the time of PCI</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Success</title>
          <description>defined as attainment of &lt; 30% residual in-stent stenosis (by visual assessment) using any percutaneous method.</description>
          <population>Intent to treat (ITT)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2"/>
                    <measurement group_id="O2" value="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>defined as: residual in-stent %DS of &lt; 30% using a percutaneous method, without cardiac death, Q-wave MI, non Q-wave MI, or repeat revasc of the target during hospitalization.</description>
        <time_frame>at the time of PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>defined as: residual in-stent %DS of &lt; 30% using a percutaneous method, without cardiac death, Q-wave MI, non Q-wave MI, or repeat revasc of the target during hospitalization.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>defined as achievement of a final residual in-stent diameter stenosis of &lt; 30% (visual assessment) using the assigned device only.</description>
        <time_frame>at the time of PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>defined as achievement of a final residual in-stent diameter stenosis of &lt; 30% (visual assessment) using the assigned device only.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7"/>
                    <measurement group_id="O2" value="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Stent Thrombosis.</title>
        <time_frame>at 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Stent Thrombosis.</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Stent Thrombosis.</title>
        <time_frame>9 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Stent Thrombosis.</title>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Revascularizations</title>
        <description>(TLR/TVR/any revascularization)both ischemia-driven and not ischemia-driven.</description>
        <time_frame>at 30 days</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Revascularizations</title>
          <description>(TLR/TVR/any revascularization)both ischemia-driven and not ischemia-driven.</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Revascularizations</title>
        <description>(TLR/TVR/any revascularization)both ischemia-driven and not ischemia-driven.</description>
        <time_frame>9 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Revascularizations</title>
          <description>(TLR/TVR/any revascularization)both ischemia-driven and not ischemia-driven.</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death, MI (Q-wave and Non Q-wave), and Ischemia-driven TLR .</title>
        <description>ITT</description>
        <time_frame>9 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death, MI (Q-wave and Non Q-wave), and Ischemia-driven TLR .</title>
          <description>ITT</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Death, MI (Q-wave and Non Q-wave), and TVR.</title>
        <time_frame>9 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Death, MI (Q-wave and Non Q-wave), and TVR.</title>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-stent Minimum Lumen Diameter (MLD).</title>
        <time_frame>at 9 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent Minimum Lumen Diameter (MLD).</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.64"/>
                    <measurement group_id="O2" value="2.17" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment Minimum Lumen Diameter (MLD).</title>
        <time_frame>at 9 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment Minimum Lumen Diameter (MLD).</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="0.57"/>
                    <measurement group_id="O2" value="2.04" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proximal Minimum Lumen Diameter (MLD).</title>
        <description>Proximal refers to the immediate 5 mm outside of the proximal end of the stent.</description>
        <time_frame>at 9 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Proximal Minimum Lumen Diameter (MLD).</title>
          <description>Proximal refers to the immediate 5 mm outside of the proximal end of the stent.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="0.65"/>
                    <measurement group_id="O2" value="2.61" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal Minimum Lumen Diameter (MLD).</title>
        <description>Distal refers to the immediate 5 mm outside of the distal end of the stent.</description>
        <time_frame>at 9 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Distal Minimum Lumen Diameter (MLD).</title>
          <description>Distal refers to the immediate 5 mm outside of the distal end of the stent.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.59"/>
                    <measurement group_id="O2" value="2.25" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>In-stent Late Loss (LL)</title>
        <description>Full Analysis Set (FAS). LL is defined as the difference between the post-procedure (immediately post placement of the stent) minimal lumen diameter (MLD) and the follow-up MLD (at 270 days). In stent is measured within the confines of the stent edges.</description>
        <time_frame>at 270 days</time_frame>
        <population>Descriptive statistics for this measure are based on one random lesion per patient, 167 patients performed angiographic follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V</title>
            <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
          </group>
          <group group_id="O2">
            <title>TAXUS® Liberté™</title>
            <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent Late Loss (LL)</title>
          <description>Full Analysis Set (FAS). LL is defined as the difference between the post-procedure (immediately post placement of the stent) minimal lumen diameter (MLD) and the follow-up MLD (at 270 days). In stent is measured within the confines of the stent edges.</description>
          <population>Descriptive statistics for this measure are based on one random lesion per patient, 167 patients performed angiographic follow-up.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.513"/>
                    <measurement group_id="O2" value="0.238" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <desc>Only serious adverse events were collected in the conduct of this trial. &quot;Other&quot; adverse events were not collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>XIENCE V</title>
          <description>Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)</description>
        </group>
        <group group_id="E2">
          <title>TAXUS® Liberté™</title>
          <description>Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Procedural complications</sub_title>
                <description>Events in this code wer failure of the stent to cross the lesion and failure of the wire to cross the lesion. There are no exact codes for these events in MedDRA.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <description>Events under Mechanical complication are plaque shifts. There is no exact code for this event in MedDRA</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Ischaemia NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The publication of the aggregate data is subject to the prior agreement of all the various sites participating in the study. Publication of the clinical data collected during the Study, can be only after notifying the SPONSOR in advance in order to allow the SPONSOR to verify compliance with confidentiality obligations and intellectual property rights of the SPONSOR.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Jose' M. Lopera</name_or_title>
      <organization>Abbott Vascular, Italy</organization>
      <phone>+39-02-516251</phone>
      <email>mariajose.lopera@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

